Prognostic role of NLR in urinary cancers: A meta-analysis

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Wei, Yong ^a   Jiang, Ya Zhi ^a   Qian, Wen Hui ^a  

^a Gaochun County Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ASIAN; BLADDER CANCER; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CAUCASIAN; DISEASE MARKER; HAZARD RATIO; HEMATOLOGICAL PARAMETERS; HUMAN; KIDNEY CARCINOMA; NEUTROPHIL TO LYMPHOCYTE RATIO; OVERALL SURVIVAL; RECURRENCE FREE SURVIVAL; TRANSITIONAL CELL CARCINOMA; URINARY TRACT CANCER; ASIAN CONTINENTAL ANCESTRY GROUP; ETHNOLOGY; FEMALE; INFLAMMATION; LEUKOCYTE COUNT; LYMPHOCYTE; LYMPHOCYTE COUNT; MALE; META ANALYSIS; MORTALITY; NEUTROPHIL; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SURVIVAL; UROLOGIC NEOPLASMS;

BIOLOGICAL MARKER;

ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INFLAMMATION; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; NEUTROPHILS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; UROLOGIC NEOPLASMS;

EID: 84898665929     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0092079     Document Type: Article

References (39)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
3. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, et al. (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411-422.
4. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, et al. (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134. (Pubitemid 46089673)
5. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, et al. (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378: 1931-1939.
6. Kutikov A, Uzzo RG, Caraway A, Reese CT, Egleston BL, et al. (2010) Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU Int 106: 218-223.
7. Cedres S, Torrejon D, Martinez A, Martinez P, Navarro A, et al. (2012) Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol 14: 864-869.
8. He W, Yin C, Guo G, Jiang C, Wang F, et al. (2013) Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte ratio as an adverse prognostic and predictive factor in metastatic colorectal cancer. Med Oncol 30: 439.
9. Pichler M, Hutterer GC, Stoeckigt C, Chromecki TF, Stojakovic T, et al. (2013) Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. Br J Cancer 108: 901-907.
10. Forget P, Machiels JP, Coulie PG, Berliere M, Poncelet AJ, et al. (2013) Neutrophil:Lymphocyte Ratio and Intraoperative Use of Ketorolac or Diclofenac are Prognostic Factors in Different Cohorts of Patients Undergoing Breast, Lung, and Kidney Cancer Surgery. Ann Surg Oncol.
11. Shafique K, Proctor MJ, McMillan DC, Qureshi K, Leung H, et al. (2012) Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow Inflammation Outcome Study. Prostate Cancer Prostatic Dis 15: 195-201.
12. Linton A, Pond G, Clarke S, Vardy J, Galsky M, et al. (2013) Glasgow Prognostic Score As a Prognostic Factor in Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel-Based Chemotherapy. Clin Genitourin Cancer.
13. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. (2000) Metaanalysis of observational studies in epidemiology: a proposal for reporting. Metaanalysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283: 2008-2012. (Pubitemid 30214957)
14. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8: 16.
15. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188. (Pubitemid 17189972)
16. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748.
17. Ohno Y, Nakashima J, Ohori M, Hatano T, Tachibana M (2010) Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. J Urol 184: 873-878.
18. Keizman D, Ish-Shalom M, Huang P, Eisenberger MA, Pili R, et al. (2012) The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer 48: 202-208.
19. Ohno Y, Nakashima J, Ohori M, Gondo T, Hatano T, et al. (2012) Followup of neutrophil-to-lymphocyte ratio and recurrence of clear cell renal cell carcinoma. J Urol 187: 411-417.
20. Cetin B, Berk V, Kaplan MA, Afsar B, Tufan G, et al. (2013) Is the pretreatment neutrophil to lymphocyte ratio an important prognostic parameter in patients with metastatic renal cell carcinoma? Clin Genitourin Cancer 11: 141-148.
21. Ohno Y, Nakashima J, Ohori M, Tanaka A, Hashimoto T, et al. (2013) Clinical variables for predicting metastatic renal cell carcinoma patients who might not benefit from cytoreductive nephrectomy: neutrophil-to-lymphocyte ratio and performance status. Int J Clin Oncol.
22. Kobayashi M, Kubo T, Komatsu K, Fujisaki A, Terauchi F, et al. (2013) Changes in peripheral blood immune cells: their prognostic significance in metastatic renal cell carcinoma patients treated with molecular targeted therapy. Med Oncol 30: 556.
23. Fox P, Hudson M, Brown C, Lord S, Gebski V, et al. (2013) Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. Br J Cancer 109: 147-153.
24. Santoni M, De Giorgi U, Iacovelli R, Conti A, Burattini L, et al. (2013) Pretreatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma. Br J Cancer 109: 1755-1759.
25. Hatakeyama S, Yoneyama T, Hamano I, Murasawa H, Narita T, et al. (2013) Prognostic benefit of surgical management in renal cell carcinoma patients with thrombus extending to the renal vein and inferior vena cava: 17-year experience at a single center. BMC Urol 13: 47.
26. Gondo T, Nakashima J, Ohno Y, Choichiro O, Horiguchi Y, et al. (2012) Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy. Urology 79: 1085-1091.
27. Krane LS, Richards KA, Kader AK, Davis R, Balaji KC, et al. (2013) Preoperative neutrophil/lymphocyte ratio predicts overall survival and extravesical disease in patients undergoing radical cystectomy. J Endourol 27: 1046-1050.
28. Azuma T, Matayoshi Y, Odani K, Sato Y, Nagase Y, et al. (2013) Preoperative neutrophil-lymphocyte ratio as an independent prognostic marker for patients with upper urinary tract urothelial carcinoma. Clin Genitourin Cancer 11: 337-341.
29. Dalpiaz O, Ehrlich GC, Mannweiler S, Martin Hernandez JM, Gerger A, et al. (2013) Validation of the pre-treatment neutrophil-lymphocyte ratio as prognostic factor in a European cohort of patients with upper tract urothelial carcinoma. BJU Int.
30. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454: 436-444.
31. Castelao JE, Yuan JM, Gago-Dominguez M, Yu MC, Ross RK (2000) Nonsteroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 82: 1364-1369. (Pubitemid 30145360)
32. Daugherty SE, Pfeiffer RM, Sigurdson AJ, Hayes RB, Leitzmann M, et al. (2011) Nonsteroidal antiinflammatory drugs and bladder cancer: a pooled analysis. Am J Epidemiol 173: 721-730.
33. Petrie HT, Klassen LW, Kay HD (1985) Inhibition of human cytotoxic T lymphocyte activity in vitro by autologous peripheral blood granulocytes. J Immunol 134: 230-234. (Pubitemid 15191502)
34. Schaider H, Oka M, Bogenrieder T, Nesbit M, Satyamoorthy K, et al. (2003) Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. Int J Cancer 103: 335-343. (Pubitemid 36076426)
35. Gueron G, De Siervi A, Vazquez E (2012) Advanced prostate cancer: reinforcing the strings between inflammation and the metastatic behavior. Prostate Cancer Prostatic Dis 15: 213-221.
36. Tsai JC, Sheu SH, Chiu HC, Chung FM, Chang DM, et al. (2007) Association of peripheral total and differential leukocyte counts with metabolic syndrome and risk of ischemic cardiovascular diseases in patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 23: 111-118.
37. Terradas R, Grau S, Blanch J, Riu M, Saballs P, et al. (2012) Eosinophil count and neutrophil-lymphocyte count ratio as prognostic markers in patients with bacteremia: a retrospective cohort study. PLoS One 7: e42860.
38. Alkhouri N, Morris-Stiff G, Campbell C, Lopez R, Tamimi TA, et al. (2012) Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease. Liver Int 32: 297-302.
39. Azab B, Jaglall N, Atallah JP, Lamet A, Raja-Surya V, et al. (2011) Neutrophillymphocyte ratio as a predictor of adverse outcomes of acute pancreatitis. Pancreatology 11: 445-452.